Clinical Trials Logo

Skin Lesion clinical trials

View clinical trials related to Skin Lesion.

Filter by:

NCT ID: NCT02193581 Completed - Skin Lesion Clinical Trials

Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging

Start date: August 30, 2017
Phase: N/A
Study type: Observational

The use of MDS to access the presence of melanoma in the skin.

NCT ID: NCT01771718 Recruiting - Skin Lesion Clinical Trials

Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy

Start date: April 2012
Phase:
Study type: Observational

The purpose of this pilot study is to employ multiphoton microscopy to non-invasively image in-vivo pigmented and non-pigmented human skin lesions for characterization of their morphologic and functional features. .

NCT ID: NCT00798798 Withdrawn - Skin Lesion Clinical Trials

Effect of Externally Implantable Tissue Expansion Device on Scar Length

Start date: April 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to assess whether brief use of an externally implantable tissue expansion device following excisional skin cancer surgery will significantly reduce the diameter of the final wound defect, and hence the length of the final linear primary closure. The secondary objective is to assess the functional benefits, if any, associated with use of the tissue expander.

NCT ID: NCT00470912 Completed - Skin Lesion Clinical Trials

Sunscreen RV 2457C in Photoinduced CLE

Start date: May 2001
Phase: Phase 3
Study type: Interventional

Lupus erythematosus (LE) is characterized by a large clinical spectrum, and sunligt is a well established factor in the induction and exacerbation of this disease. In all subsets of LE, skin lesions occur preferentially in sun-exposed areas. Previous studies have demonstrated that the lesions in LE patients reproduced in controlled experimental conditions. The initial reports suggested that the action spectrum for the LE was in the UVB range (290 to 320 nm), but more recent studies have demonstrated that UVA (320 to 400 nm) can contribute to the induction of LE skin lesions. Antimalarial agents and topical steroids are the main treatments of chronic LE. The second line therapies include retinoids, sulfones, immunosuppressor agents, systemic corticosteroid and thalidomide. Moreover, patients are advised to avoid sun, to wear sunprotective clothing and to apply sunscreen. The aim of this study was to assess the efficacy of a sunscreen milk with high protection factor against UV-B and UV-A, used exclusively, in the photoinduced LE.